Related references
Note: Only part of the references are listed.Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology
H. Ruth Ashbee et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2014)
Fungal allergy in asthma-state of the art and research needs
David W. Denning et al.
CLINICAL AND TRANSLATIONAL ALLERGY (2014)
A comprehensive regulatory framework to address the unmet need for new antibacterial treatments
John H. Rex et al.
LANCET INFECTIOUS DISEASES (2013)
Systems-level antimicrobial drug and drug synergy discovery
Terry Roemer et al.
NATURE CHEMICAL BIOLOGY (2013)
Voriconazole for chronic pulmonary aspergillosis: a prospective multicenter trial
J. Cadranel et al.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2012)
Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010
Theo Vos et al.
LANCET (2012)
Triazole Fungicides Can Induce Cross-Resistance to Medical Triazoles in Aspergillus fumigatus
Eveline Snelders et al.
PLOS ONE (2012)
Hidden Killers: Human Fungal Infections
Gordon D. Brown et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
Decreased Infection-Related Mortality and Improved Survival in Severe Aplastic Anemia in the Past Two Decades
Jessica M. Valdez et al.
CLINICAL INFECTIOUS DISEASES (2011)
The Nationwide Austrian Aspergillus Registry: a prospective data collection on epidemiology, therapy and outcome of invasive mould infections in immunocompromised and/or immunosuppressed patients
S. Perkhofer et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2010)
Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis
DW Denning et al.
CLINICAL INFECTIOUS DISEASES (2002)